Feasibility study of post-SBRT adjuvant chemotherapy with tegafur-uracil in patients with stage I non-small cell lung cancer

Feasibility study of post-SBRT adjuvant chemotherapy with tegafur-uracil in patients with stage I non-small cell lung cancer - Feasibility study of post-SBRT UFT in stage I NSCLC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1091220068

Enrollment

Registered

2011-07-31

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage I Non small cell lung cancer

Interventions

Intervention type:DRUG Name of intervention:tegafur-uracil Dose form / Japanese Medical Device Nomenclature:CAPSULE Route of administration / Site of application:ORAL Dose per administration:200 100-2

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. pathologically or cytologically proved non-small cell lung cancer 2. clinical stage I (T1>=2cm,T2==2cm and =<4cm 6. Being pulmonary tumor 7. Older than 20 years old 8. principal organs have normal function 9. estimated survival more than 6 months 10. considered inoperable or refused operation 11. got informed consent

Exclusion criteria

Exclusion criteria: 1. pulmonary fibrosis found on chest radiography 2. syncronous or metachronous cancer with disease free interval within 5 years 3. had a history of chemotherapy for NSCLC within 5 years 4. indicated progressive disease before administration of UFT 5. under pregnancy 6. had angina, cardiac infarction or heart failure within 3 months with poor control 7. having poor control DM 8. having some infection 9. have fever higher than 38 degrees 10. routine use of steroids

Design outcomes

Primary

Measure	Time frame
feasibility	—

Secondary

Measure	Time frame
safety, relapse free survival, local relapse free survival, overall survival	—

Countries

Japan

Contacts

Public ContactOsamu Suzuki

Osaka Medical Center for Cancer and Cardiovascular Diseases

osamu-s@umin.ac.jp+81-6-6972-1181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026